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Abstract
Purpose: To determine the ef® cacy and toxicity of docetaxel as ® rst-line chemotherapy in adult patients with locally
advanced and/or metastatic soft tissue sarcoma (STS).
Patients/methods. Thirty eligible patients, with histologically proven STS, Eastern Cooperative Oncology Group (ECOG)
performance status 0± 2 and bidimensionally measurable disease, entered this study. None had received previous
chemotherapy. Docetaxel 100 mg m
2 2 was given as a 1-h intravenous infusion every 3 weeks. Patients were evaluable for
response, evaluated by WHO criteria, after one cycle of chemotherapy and toxicity was graded by NCIC-CTG common
toxicity criteria.
Results. One hundred and thirty two cycles were aldministered, with a range per patient of 1± 9. The median delivered
dose intensity was 32.2 mg m
2 2 week
2 1 (planned 33.3 mg m
2 2 week
2 1 ) and 67% of patients received $ 90% planned
dose intensity. There were three partial responses (10.7%; 95% con® dence interval 2.3± 28.2) with a median duration of
7 months (range 6.4± 8.3 months). Thirty patients were evaluable for non-haematological toxicity and 28 for haematolog-
ical toxicity (repeat counts were not available in two patients). Haematological toxicity was moderately severe, with 18
(64%) patients experiencing at least one episode of grade 4 neutropenia, and 7 (25%) patients experiencing febrile
neutropenia.
Conclusions. In this study, activity of docetaxel in adult chemotherapy-naõÈ ve patients with advanced STS was modest
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Introduction
In the past 10 years, there has been little progress in
the management of metastasized soft tissue sarcoma
(STS). A minority of patients have long-term
bene® t from resection of lung metastases.
1 No new
active agents have been identi® ed since doxorubicin
and dacarbazine in the 1970s, and ifosfamide in the
mid-1980s.
2 Despite encouraging data from single-
arm studies, randomized trials have failed to dem-
onstrate convincingly the superiority of combination
chemotherapy
3 compared with single-agent doxoru-
bicin. Similarly, dose intensi® cation of standard
agents or regimens, which have produced promising
response rates in pilot studies, have not been
proven more active in randomized trials.
4 The need
for active new agents is clear.
To optimize the possibility of identifying new
active drugs for this disease, the Canadian Sarcoma
Group working with the NCIC Clinical Trials
Group has pursued for several years, a policy of
offering investigational drug treatment to chemo-
therapy-naõÈ ve patients, with the option to proceed
to standard drugs if initial treatment fails.
Docetaxel (Taxotere) is a semi-synthetic ana-
logue of paclitaxel, prepared using a precursor
extracted from the needles of the European yew,
Taxus baccata.
5 By enhancing microtubule assembly
and inhibiting depolymerization of tubulin, doc-
etaxel causes accumulation of microtubules in the
cell and, by blocking cells in the M-phase of the cell
cycle, prevents cell division.
6 Based on more potent
in vivo antitumour activity compared with pacli-
taxel, in B16 melanoma and a variety of colon
carcinomas,
7 as well as a favourable toxicity pro® le
in animals, docetaxel was selected for human stud-
ies. Comparing the toxicities observed in the ® ve
human phase I trials, the highest maximum toler-
ated dose (MTD) and dose intensity were achieved
with the 1-h 3-weekly infusion schedule.
8 The dose
selected for this, and other phase II studies, was
100 mg m
2 2.
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Patients and Methods
Criteria for eligibility
Patient eligibility criteria included: histologically
proven STS; bidimensionally measurable metastatic
or locally recurrent disease incurable with standard
therapy; ECOG performance status 0, 1 or 2
and life expectancy of 12 weeks or greater; age $ 18
years; no previous chemotherapy; no prior
malignancy; granulocytes . 2.0 3 10
9/l, platelets
. 100 3 10
9/l, creatinine and bilirubin # 1.5 3
upper normal limit; signed informed consent.
Patients were not permitted to have prior radiation
to the sole site of measurable disease.
Trial design and therapeutic regimen
Docetaxel was supplied by Rho Ã ne Poulenc-Rorer Ltd
(Ville St Laurent, Quebec, Canada). It was given at a
starting dose of 100 mg m
2 2, diluted in 250 ml of
0.9% sodium chloride or 5% dextrose solution,
infused over 1 h, repeated every 3 weeks. All patients
were premedicated for possible hypersensitivity with
20 mg of dexamethasone orally 12 and 6 h prior to
docetaxel, and 50 mg of diphenhydramine and 50 mg
of ranitidine (or 300 mg of cimetidine) given slowly
intravenously prior to docetaxel.
Doses were adjusted for myelosuppression based
on nadir blood counts. For an absolute granulocyte
count of, 0.5 3 10
9/l for 7 days or a platelet count
, 25 3 10
9/l, febrile neutropenia, $ grade 3 infec-
tion or bleeding requiring transfusion, the dose in
the next cycle was reduced by 25%. If the treatment
day count showed an absolute granulocyte count of
, 1.5 3 10
9/l or platelet count of , 100 3 10
9/l,
treatment was delayed until recovery. Haematopoi-
etic colony stimulating factors were not used. If
patients developed grade 3 peripheral neuropathy,
they were taken off protocol therapy, and a dose
reduction of 25% was applied for grade 2 neurotox-
icity. For other toxic effects $ grade 3, drug admin-
istration was delayed until resolution to # grade 1,
and then reinstituted with a dose reduction of 25%.
Once doses had been reduced for toxicity, they were
not re-escalated.
Patient evaluation
Patients were evaluable for response after receiving
one cycle of therapy (3 weeks on the study).
Responding patients continued on the study until
evidence of disease progression, or the occurrence of
unacceptable toxicity. Patients with complete (CR)
or partial (PR) response continued on therapy for a
maximum of four cycles after documentation of
response. Patients with stable disease (SD) contin-
ued on therapy for a maximum of six cycles. WHO
criteria for response were employed and toxic effects
were graded according to the NCIC-CTG common
toxicity criteria.
Results
Between April 1994 and June 1995, 32 patients
were enrolled from eight Canadian centres. Two
patients were ineligible: one had no measurable
lesions and in the other the histology was not STS.
Two further patients were not evaluable for
response and haematological toxicity. The condition
of one patient deteriorated suddenly with onset of
congestive heart failure, renal failure and sepsis, and
she died 6 days after the ® rst dose of docetaxel. The
second patient did not complete the ® rst dose of
docetaxel because of a severe hypersensitivity reac-
tion and went off study. Table 1 describes the
characteristics of eligible patients. A majority of
patients (18) had lung metastases, other common
sites of disease being nodes, soft tissue and within
the abdomen/pelvis/retroperitoneum.
One hundred cycles were administered at the
starting dose of 100 mg m
2 2 every 3 weeks, and 26
cycles at the reduced dose level of 75 mg m
2 2 every
3 weeks (a 25% dose reduction). One and ® ve cycles
were administered at dose levels 55 and , 50 mg
m
2 2 respectively. The number of cycles per patient
ranged from one to nine. The planned dose intensity
was 33.3 mg m
2 2 week
2 1 and the achieved median
dose intensity was 32.24 mg m
2 2 week
2 1 (range
Table 1. Patient characteristics (n 5 30 eligible)
Characteristics Number
Sex
Female 18
Male 12
Performance status (ECOG)
0 14
1 11
2 5
Prior therapy
Chemotherapy 0
Radiotherapy 14
Hormone therapy 1
Immunotherapy 0
Pathology
Leiomyosarcoma 11
gastointestinal 6
trunk 2
uterine 3
Malignant ® brous histiocytoma 7
Mixed mullerian sarcoma 2
Endometrial stromal sarcoma 2
Haemangiopericytoma 2
Undifferentiated 2
Other* 4
Number of sites of disease
1 11
2 14
3 3
4 or more 2
*Alveolarsoftparts sarcoma, angiosarcoma,liposarcoma,
malignant Schwannoma.Docetaxel in soft tissue sarcoma 31
Table 2. Haematological toxicity* (n 5 28 evaluable)
Toxicity grade
Median nadir
Criteria (range) 0 1 2 3 4
Haemoglobin (g/l) 104 5 11 8 3 1
(62± 149)
White cell count (3 10
9/l) 1.7 3 2 5 12 6
(0.7± 13.9)
Granulocytes (3 10
9/l) 0.4 6 1 1 2 18
(0.2± 7.5)
Platelets (3 10
9/l) 259 26 2 0 0 0
(136± 564)
*Worse by patient while on study.
Table 3. Non-haematological toxicityÐ worst by patient* (n 5 30 evaluable)
Number by grade
Incidence
Type 1 2 3 4 (%)
Alopecia 13 8 2 0 77
Lethargy 8 6 4 0 60
Nausea 6 4 0 0 33
Vomiting 6 2 0 0 27
Anorexia 4 2 1 0 23
Diarrhoea 6 5 1 0 40
Infection 4 1 0 0 17
Febrile neutropenia 0 0 7 0 23
Fever (no infection) 3 1 0 0 13
Dyspnoea 1 1 0 1 10
Oedema 4 2 2 0 27
Myalgia 1 0 2 0 10
Arthralgia 2 0 1 0 10
Peripheral neuropathyÐ motor 3 1 1 0 17
Peripheral neuropathyÐ sensory 9 4 0 0 43
*Felt to be drug related.
1.25± 33.60 mg m
2 2 week
2 1). Sixty-seven per-cent
of patients were able to receive $ 90% of the
planned dose intensity.
Myelosuppression could be evaluated in 28
patients having interim blood counts. Neutropenia
was common and moderately severe, 18 (64%)
patients experiencing at least one episode of grade 4
neutropenia (Table 2). Febrile neutropenia was
reported in seven (25%) patients. Two other
patients had a documented grade 4 infection not
thought to be related to therapy. In 30 evaluable
patients, the most frequently observed non-haema-
tological toxicities thought to be drug related were
alopecia (77%), lethargy (60%), sensory neuropathy
(43%), oedema (27%), nausea (33%), vomiting
(27%), anorexia (23%) and diarrhoea (40%), but
most of these were mild (Table 3).
In 28 evaluable patients, there were three PRs
(10.7%; 95% con® dence interval (CI) 2.3± 28.2%)
with a median duration of 7 months (range 6.4± 8.3
months). Thirteen patients had lasting 5.4 months
(range 2.1± 20.9 months). The median number of
cycles received by these patients was six (range
3± 14). Two of the PRs occurred in patients with
leiomyosarcoma (one uterine, one retroperitoneal),
the most common histological type entered into the
study. The third response occurred in a patient with
malignant ® brous histiocytoma. Two of the
responses occurred in lung metastases, and the third
in a retroperitoneal mass.
Discussion
The taxanes, paclitaxel and docetaxel, are a new class
of cytotoxic drugs with activity in a variety of solid
tumours. Paclitaxel was the ® rst analogue to be tested,
and was shown to be active in platinum-resistant
ovarian cancer
9 and also in breast cancer.
10 A dif® cult
extraction process, from the bark of the Paci® c yew,
initially limited supplies and accelerated the search for
semi-synthetic analogues, such as docetaxel.
In phase II trials, docetaxel has shown signi® cant
activity, with reproducible response rates of greater
than 20%, in breast cancer, non-small cell lung,
ovarian, gastric, squamous head and neck and blad-
der cancers.
11
Both analogues have been evaluated in advanced/
metastatic STS. There have been two studies of32 V. Bramwell et al.
paclitaxel at a dose of 250 mg m
2 2 every 3 weeks.
In the larger South West Oncology Group (SWOG)
study
12, there was one CR and 5 PRs for an overall
response rate of 12.5% (95% CI 4.7± 25.3%), in 48
patients none of whom had received prior chemo-
therapy. A lower response rate of one PR (3.6%) in
28 patients, 11 of whom had received prior chemo-
therapy, was reported by Waltzman et al.
13 Gian et
al.
14 did not observe any responses in 10 patients
with STS (four had received prior chemotherapy)
treated with 200 mg m
2 2 every 3 weeks of pacli-
taxel.
In contrast, Van Hoesel et al.,
15 for the European
Organization for Research and Treatment of Cancer
(EORTC), observed ® ve PRs in 29 patients (17.2%;
95% CI 6± 36%) treated with docetaxel 100 mg m
2 2
every 3 weeks, all of whom had received previous
chemotherapy. These encouraging results prompted
the EORTC to undertake a randomized phase III
study comparing 100 mg m
2 2 every 3 weeks of
docetaxel with 75 mg m
2 2 every 3 weeks of doxoru-
bicin. This study has just been reported in abstract
form.
16 With 86 patients on study and 73 available
for analysis, the preliminary response rates were 0%
for docetaxel and 27% for doxorubicin, the latter
being very similar to previous EORTC experience
with single-agent doxorubicin.
The current study was started shortly after publi-
cation in abstract form
17 of the preliminary results of
the EORTC phase II study describing, at that time,
® ve PRs (21.7%) in 23 patients. We hoped to
con® rm, and perhaps improve on, these results in
chemotherapy-naõÈ ve patients. The low response rate
seen in our study was surprising, but is less so now
that it is seen in the context of the more recent
EORTC phase III results.
16 It is intriguing that in a
different tumour type, small-cell lung cancer, a
higher response rate of 25%
18 was seen in previously
treated patients receiving docetaxel, compared with
8%
19 in a second study including only chemo-
therapy-naõÈ ve patients. As the EORTC study
17
includes a cross-over component this may provide
further data on this issue.
Thirteen patients achieved SD. Rapidly progress-
ive disease at entry was not a protocol requirement,
but most Canadian oncologists use chemotherapy in
the setting of progressive symptomatic metastatic
disease, and this disease stabilization may be an
additional indicator of drug activity.
It has been suggested that leiomyosarcomas, par-
ticularly those of bowel metastatic to liver, are less
responsive to chemotherapy. However, leiomyosar-
comas (including those of gastrointestinal origin
now known as stromal tumours) may comprise one-
third to one-half of tumours in clinical trials of
metastatic STS. This is true of our study (39%), the
phase II
15 and III
17 studies of the EORTC (41%;
36%) and for the SWOG
12 and Waltzman studies
13
of paclitaxel, 54% and 53% respectively. This simi-
lar distribution does not provide a reason for the
discrepant response rates. The most likely expla-
nation is chance occurrence in small patient popula-
tions.
Conclusions
Despite initial promise, data from this study, and
more recent phase II and III studies, do not suggest
that taxanes have major activity in adult STS.
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